Robust Salmonella metabolism
Nature 440, 303-307 (16 March 2006) | doi:10.1038/nature04616; Received 12 December 2005; Accepted 1 February 2006 >>NEW<<
Daniel Becker1,5,*, Matthias Selbach2,5,*, Claudia Rollenhagen1,5,*, Matthias Ballmaier3, Thomas F. Meyer1, Matthias Mann2 and Dirk Bumann1,4
1.Max-Planck-Institute for Infection Biology, Department of Molecular Biology
2.Max-Planck-Institute of Biochemistry, Department of Proteomics and Signal Transduction, D-82152 Martinsried, Germany
3.Hannover Medical School, Flow Cytometry Core Facility, D-30625 Hannover, Germany
4.Hannover Medical School, Institute of Immunology, 'Mucosal Infections' Junior Research Group OE 9421, D-30625 Hannover, Germany
5.*These authors contributed equally to this work
New antibiotics are urgently needed to control infectious diseases. Metabolic enzymes could represent attractive targets for such antibiotics, but in vivo target validation is largely lacking. Here we have obtained in vivo information about over 700 Salmonella enterica enzymes from network analysis of mutant phenotypes, genome comparisons and Salmonella proteomes from infected mice. Over 400 of these enzymes are non-essential for Salmonella virulence, reflecting extensive metabolic redundancies and access to surprisingly diverse host nutrients. The essential enzymes identified were almost exclusively associated with a small subgroup of pathways, enabling us to perform a nearly exhaustive screen. Sixty-four enzymes identified as essential in Salmonella are conserved in other important human pathogens, but almost all belong to metabolic pathways that are inhibited by current antibiotics or that have previously been considered for antimicrobial development. Our comprehensive in vivo analysis thus suggests a shortage of new metabolic targets for broad-spectrum antibiotics, and draws attention to some previously known but unexploited targets.
http://www.nature.com/nature/journal/v440/n7082/full/nature04616.html
rss
Top
Print